Cooperation agreements in biotechnology allow us to observe the complexity surrounding alliances. The market globalization, the exorbitant costs of R&D and the rapid changes in technology, are arguably amongst the principal reasons that push companies to establish cooperation agreements. Biotechnology companies use this instrument to develop external features in the search for resources and missing expertise. This paper sets out to identify if such cooperation agreements in biotechnology companies are an advantage in themselves, sufficient for the acquisition of new capabilities and if they help the growth of these companies. For this approach, a private database of companies in the two most advanced countries in this sector: United States and United Kingdom, will be used.Los acuerdos de cooperación en Biotecnología nos permiten observar la complejidad de las alianzas. La globalización del Mercado, los excesivos costos de I+D y los rápidos cambios en la tecnología, son discutiblemente las principales razones de porque las compañías son conducidas a establecer acuerdos de cooperación. Las compañías biotecnológicas usan este instrumento para desarrollar características externas en búsqueda de recursos y expertise inexistente. El siguiente documento identifica si aquellos acuerdos de cooperación son una verdadera ventaja en las compañías biotecnológicas, si éstos son suficientes para la adquisición de nuevas capacidades y si éstos son efectivamente beneficiosos para dichas compañías. Para ésta aproximación, una base de datos privada de dos de los países más avanzados en éste sector fueron consultadas: Estados Unidos y Reino Unido.Cooperation agreements in biotechnology allow us to observe the complexity surrounding alliances. The market globalization, the exorbitant costs of R&D and the rapid changes in technology, are arguably amongst the principal reasons that push companies to establish cooperation agreements. Biotechnology companies use this instrument to develop external features in the search for resources and missing expertise. This paper sets out to identify if such cooperation agreements in biotechnology companies are an advantage in themselves, sufficient for the acquisition of new capabilities and if they help the growth of these companies. For this approach, a private database of companies in the two most advanced countries in this sector: United States and United Kingdom, will be used.